If you have ever received a letter from your insurance company saying a drug is “non-formulary” or “requires a tier exception,” you know the frustration of the appeals process. In 2026, that process has become significantly steeper. As insurers lean heavily on AI-driven utilization management and stricter formulary designs to control costs, the “exception” window is closing.
Requests that might have been rubber-stamped two years ago are now facing automated rejections. According to 2026 data from Avalere Health, plans are aggressively narrowing their criteria for what constitutes a valid medical exception. Here are the six specific types of coverage exceptions that are becoming much harder to win this year.
1. The “Tier” Exception for Specialty Drugs
In the past, if you were prescribed a Tier 4 drug with a high copay, you could often apply for a “Tier Exception” to get it covered at the cheaper Tier 2 or Tier 3 price. In 2026, this door is slamming shut. Many plans have reclassified their most expensive medications into a “Specialty Tier” (Tier 5 or 6). Under CMS guidelines for 2026, drugs placed in this specific “Specialty” category are exempt from tiering exceptions. If your medication is on this list, no amount of doctor letters can lower the copay; your only option is to apply for financial assistance or switch drugs.
2. “Step Therapy” Bypass Requests
“Step Therapy” (or “Fail First”) requires you to try cheaper drugs before the insurer pays for the expensive one. In 2026, skipping the line has become nearly impossible. Insurers have updated their 2026 Step Therapy Protocols to require “documented failure” of not just one, but often two or three alternative therapies. Simply arguing that “I’ve been on this drug for years” (Grandfathering) is no longer a guaranteed pass. Unless you can prove you had a specific adverse medical reaction to the cheaper alternatives, the AI review system will automatically deny the bypass request.
3. Off-Label Use for GLP-1s
The most scrutinized exception in 2026 involves GLP-1 agonists (like Ozempic or Mounjaro). While these drugs are FDA-approved for diabetes, many patients seek exceptions for weight loss or other off-label uses. Insurers have responded with a “Diagnosis Code Hard Lock.” According to Blue Cross Blue Shield’s 2026 updates, if the claim does not include a confirmed Type 2 Diabetes diagnosis code (E11), the system rejects it instantly. “Pre-diabetes” or “Metabolic Syndrome” exception requests are being denied at record rates as payers try to stem the tide of spending.
4. Quantity Limit Exceptions
Did your doctor write a prescription for 60 pills a month, but your plan only covers 30? Getting a “Quantity Limit Exception” in 2026 requires more than just a note saying “patient needs higher dose.” New 2026 Formulary Restrictions show that plans now demand clinical charts proving that the standard dose failed to control symptoms and that the higher dose is safe. For pain medications and sleep aids, these requests trigger a “Complex Medical Review,” often delaying care for 14 to 30 days while a human auditor reviews your file.
5. Non-Formulary “Convenience” Exceptions
Patients often ask for a non-formulary drug because it has fewer side effects or is easier to take (e.g., a once-weekly pill vs. a daily one). In 2026, “Convenience” is officially a dirty word in appeals. Unless the formulary alternative causes a “debilitating side effect” or a severe allergic reaction, exception requests based on “better tolerance” or “lifestyle fit” are being systematically denied. The bar for “medical necessity” has been raised: you must prove the covered drug is harmful, not just less effective.
6. Immediate “Brand Name” Requests
Finally, the “Dispense as Written” (DAW) exception is fading. If a generic is available, plans in 2026 are enforcing “Mandatory Generic” rules with fewer loopholes. Even if your doctor writes “Brand Medically Necessary,” many plans will now cover the drug only if you pay the difference in cost (the “Ancillary Charge”) yourself. Getting a true coverage exception—where the plan pays the full cost of the brand name—now requires proving a specific allergy to the inactive ingredients (fillers) in the generic version, verified by an allergist.
The “Letter of Necessity” is No Longer Enough
The days of a simple doctor’s note unlocking coverage are over. In 2026, winning an exception requires data: dates of failed treatments, specific diagnosis codes, and lab results.
If you are fighting a denial, do not just appeal—ask for the “Clinical Criteria” used to make the decision. By law, they must send you the specific checklist they used to say “No.”
